COX1 vs COX2

Well, I didn't really have a grip on why COX 2 inhibitors could increase the risk of cardiovascular events. This article (BMJ 2006;Vol 332 :895-8) really explains it well. I can now think of it as a balance between prostacyclin mediated repair effects at a site of damaged vascular endothelium (inhibited by COX2) and platelet aggregation (inhibited by COX1). The COX2 specific NSAID's diminish the repair and do nothing to the platelets, the non specific NSAID's have an effect on both, reducing the risk of an event. I think....